Seven abstracts on Lantheus' PET imaging candidates to be presented at ASNC2010

Lantheus Medical Imaging, Inc., a worldwide leader in diagnostic medical imaging, today announced that seven abstracts related to two of the company's cardiac Positron Emission Tomography (PET) imaging candidates will be presented at ASNC2010, the 15th Annual Scientific Session of the American Society of Nuclear Cardiology, being held September 23-26, 2010 in Philadelphia. Data being presented include preliminary results from a single site Phase 2 study on flurpiridaz F 18 (formerly known as BMS747158), a myocardial perfusion PET imaging candidate in development to diagnose coronary artery disease, and Phase 1 data on LMI 1195, a novel cardiac neuronal PET imaging candidate. These abstracts will be highlighted in a series of poster presentations at the meeting.

“Independence of myocardial functional parameters (LVEF, EDV and ESV) across a large range of acquisition times as measured from a novel F-18 radiotracer, flurpiridaz F 18”

"Lantheus is pleased that seven abstracts will be presented at ASNC2010 highlighting important data on our cardiovascular imaging pipeline candidates," said Don Kiepert, President and Chief Executive Officer of Lantheus Medical Imaging, Inc. "These data continue to support the potential of PET technology for the diagnosis and evaluation of coronary artery disease and heart failure. We believe that next generation medical imaging tools like flurpiridaz F 18 and LMI 1195 can ultimately provide physicians with improved non-invasive and cost-effective options to evaluate and help manage cardiovascular diseases."

The schedule and abstract information for the poster presentations are listed below.

Presentations featuring flurpiridaz F 18:

  • "Multicenter development of normal perfusion and function limits for stress and rest flurpiridaz F 18 cardiac PET," Piotr J. Slomka, et al., Friday, September 24, 11:45 a.m.-1:15 p.m. (# 9.14)
  • "Independence of myocardial functional parameters (LVEF, EDV and ESV) across a large range of acquisition times as measured from a novel F-18 radiotracer, flurpiridaz F 18," James A. Case, et al., Friday, September 24, 11:45 a.m.-1:15 p.m. (# 9.15)
  • "Iterative technique for optimizing injected tracer dosage and acquisition time for F-18 labeled myocardial perfusion tracer flurpiridaz F 18," James A. Case, et al., Friday, September 24, 11:45 a.m.-1:15 p.m. (# 9.17)
  • "Comparison of myocardial stress perfusion defect assessment using 99mTc sestamibi SPECT vs 18F-BMS747158 PET," Balaji K. Tamarappoo, et al., Saturday, September 25, 12:00-1:30 p.m. (# 31.14)
  • "Comparison of 18F-BMS747158 and 82Rb PET vs SPECT for detection of myocardial ischemia," Daniel S. Berman, et al., Saturday, September 25, 12:00-1:30 p.m. (# 31.17)
  • "Preliminary results of absolute quantification of rest and stress myocardial blood flow with flurpiridaz F 18 PET in normal and coronary artery disease patients in a single-center study," Jamshid Maddahi, et al., Saturday, September 25, 12:00-1:30 p.m. (# 31.18)

Presentation featuring LMI 1195:

  • "Tracer kinetic modeling of [18F]LMI1195, a new PET imaging agent targeting cardiac norepinephrine transporter," Ajay V. Srivastava, et al., Friday, September 24, 11:45 a.m.-1:15 p.m. (# 9.19)
Source:

Lantheus Medical Imaging, Inc.

Advertisement

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.
Post a new comment
Post
You might also like... ×
DeNovix introduces first imaging cell counter without slides